Group 1: Company Overview - Huaman Biotechnology Co., Ltd. - B is a biopharmaceutical company established in 2012, focusing on developing protein drugs for wound healing therapies [4] - Nanhua Futures Co., Ltd. is one of the first companies in China's futures industry, providing global financial services and ranked eighth among all futures companies in China by total revenue in 2024 [9] - Impression Dahongpao Co., Ltd. is a state-owned cultural tourism service enterprise based in Wuyishan, Fujian Province, with operations in performance services, cultural tourism town business, and tea hotel business [21] Group 2: IPO Details - Huaman Biotechnology plans to issue 17.6488 million H-shares with a price range of HKD 38.20-51.00, and the subscription period is from December 12 to December 17, 2025 [2] - Nanhua Futures plans to issue 108 million H-shares with a price range of HKD 12.00-16.00, and the subscription period is also from December 12 to December 17, 2025 [7] - Impression Dahongpao plans to issue 36.1 million H-shares with a price range of HKD 3.47-4.10, with the same subscription period [19] Group 3: Financial Performance - Huaman Biotechnology reported revenues of RMB 471,700 in 2023 and net losses of RMB 1.0519 billion, RMB 2.1225 billion, and RMB 1.6410 billion for the years 2023, 2024, and the nine months ending September 30, 2025, respectively [6] - Nanhua Futures reported revenues of RMB 954.41 million, RMB 1.29287 billion, and RMB 1.35484 billion for the years 2022, 2023, and 2024, with profits increasing from RMB 245.91 million in 2022 to RMB 402.82 million in 2023 [12] - Impression Dahongpao's revenues were approximately RMB 63.04 million, RMB 143.89 million, and RMB 137.20 million for the years 2022, 2023, and 2024, with net profits of RMB 47.50 million in 2023 [23]

Core Viewpoint - BenQ Hospital (02581.HK) plans to globally offer 67 million shares, with a maximum offer price of HKD 11.68 per share, aiming to raise approximately HKD 704 million for various expansion and operational purposes [1] Group 1: Share Offering Details - The global offering consists of 6.7 million shares for Hong Kong and 60.3 million shares for international investors [1] - The subscription period is set from December 12 to December 17, with an entry fee of approximately HKD 5,898.90 for a board lot of 500 shares [1] - The expected net proceeds from the offering are HKD 626 million, which will be used for hospital expansion, potential investments and acquisitions, upgrading to a "smart hospital," and general working capital [1] Group 2: Financial Performance - The company's net profit for the fiscal years ending June 30, 2023, 2024, and the first half of 2025 is projected to be CNY 167 million, CNY 109 million, and CNY 48.704 million, reflecting year-on-year changes of 86.99%, -34.95%, and -23.18% respectively [2] Group 3: Strategic Partnerships and Market Position - The company has secured cornerstone investors including He Rong Technology Co., Ltd., He Fu (China) Medical Technology Co., Ltd., and Suzhou Zhanxing Investment Fund Partnership [1] - BenQ Hospital draws on advanced hospital management practices from Taiwan and operates as a private for-profit general hospital group in mainland China [1] Group 4: Listing Information - The company is expected to be listed on the main board by December 22, 2025, with China International Capital Corporation Hong Kong Securities Limited and Citigroup Global Markets Asia Limited acting as joint sponsors [1]

Group 1 - The company, BenQ Hospital, plans to globally offer 67 million shares, with 6.7 million shares available in Hong Kong and 60.3 million shares for international sale [1] - The subscription period is set from December 12 to December 17, with a maximum offer price of HKD 11.68 per share and an entry fee of approximately HKD 5,898.90 for a trading unit of 500 shares [1] - The total expected fundraising amount is HKD 704 million, with a net amount of HKD 626 million, which will be used for hospital expansion and upgrades, potential investments and acquisitions, smart hospital upgrades, and general working capital [1] Group 2 - The company has introduced cornerstone investors including He Rong Technology Co., Ltd., He Fu (China) Medical Technology Co., Ltd., and Suzhou Zhanxing Investment Fund Partnership [1] - BenQ Hospital is expected to be listed on the main board by December 22, 2025, with China International Capital Corporation Hong Kong Securities Limited and Citigroup Global Markets Asia Limited acting as joint sponsors [1] - The company draws on advanced hospital management experience from Taiwan and operates as a private for-profit general hospital group in mainland China [1] Group 3 - For the fiscal years 2023, 2024, and the first half of 2025 ending June 30, the company's net profits are projected to be CNY 167 million, CNY 109 million, and CNY 48.704 million, reflecting year-on-year changes of 86.99%, -34.95%, and -23.18% respectively [2]

明基醫院集團股份有限公司 BenQ BM Holding Cayman Corp. （於開曼群島註冊成立的有限公司） 股份代號 : 2581 全球發售 聯席保薦人、整體協調人、聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管理人及聯席牽頭經辦人 重要提示 閣下如對本招股章程的任何內容有任何疑問，應徵求獨立專業意見。 BenQ BM Holding Cayman Corp. 明基醫院集團股份有限公司 （於開曼群島註冊成立的有限公司） 全球發售項下的發售股份數目 ： 67,000,000股發售股份 香港發售股份數目 ： 6,700,000股發售股份（可予重新分配） 國際發售股份數目 ： 60,300,000股發售股份（可予重新分配） 最高發售價 ： 每股發售股份11.68港元，另加1% 經紀佣金、0.0027%證監會交易徵費、 0.00015%會財局交易徵費及 0.00565%聯交所交易費（須於申請 時以港元繳足，多繳款項可予退還） 面值 ： 每股股份1.00美元 股份代號 ： 2581 聯席保薦人、整體協調人、聯席全球協調人、 聯席賬簿管理人及聯席牽頭經辦人 聯席全球協調人、聯席賬簿管 ...

香港交易及結算所有限公司、香港聯合交易所有限公司（「聯交所」）及香港中央結算有限公司 （「香港結算」）對本公告的內容概不負責，對其準確性或完整性亦不發表任何聲明，並明確表 示概不就因本公告全部或任何部分內容而產生或因倚賴該等內容而引致的任何損失承擔任何責 任。 除非本公告另有界定，否則本公告所用詞彙與明基醫院集團股份有限公司（「本公司」）日期為 2025年12月12日的招股章程（「招股章程」）所界定者具有相同涵義。 本公告僅供參考，並不構成收購、購買或認購任何證券的邀請或要約。本公告並非招股章程。 潛在投資者在決定是否投資於發售股份前，應細閱招股章程以了解下文所述有關全球發售的詳 細資料。投資者應僅依賴招股章程所載資料作出有關發售股份的任何投資決定。 本公告不會直接或間接於或向美國（包括其領土及屬地、美國任何州及哥倫比亞特區）發佈、刊 發、派發。本公告並不構成或組成在美國境內或於任何其他司法權區購買或認購證券的任何要 約或招攬的一部分。本公告所述證券並無亦不會根據1933年美國證券法（經不時修訂）（「美國 證券法」）或美國任何州或其他司法權區的證券法登記。該等證券不得在美國境內或向美國人士 （定義見美國證券法 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Post Hearing Information Pack, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Post Hearing Information Pack. Post Hearing Information Pack of BenQ BM Holding Cayman Corp. 明基醫院集團股份有限公司 (the "Company") (A company incorporat ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本聆訊後資料集的內容概不負責，對其準確性或 完整性亦不發表任何聲明，並表明概不就因本聆訊後資料集全部或任何部分內容而產生或依賴該等內容而 引致的任何損失承擔任何責任。 BenQ BM Holding Cayman Corp. 明基醫院集團股份有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） 聆訊後資料集 警告 本聆訊後資料集乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會的要求而刊 發，僅用作向香港公眾人士提供資料。 本聆訊後資料集為草擬本，其所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件，即表示閣下 知悉、接納並向本公司、其各自的聯席保薦人、整體協調人、顧問及包銷團成員表示同意： 倘在適當時候向香港公眾人士提出要約或邀請，有意投資者務請僅依據於香港公司註冊處處長註冊的本公 司招股章程作出投資決定。該文件的文本將於發售期內向公眾人士派發。 (a) 本文件僅為向香港公眾人士提供有關本公司的資料，概無任何其他目的。投資者不應根據本文件所 載資料作出投資決定； (b) 在聯交所網站登載本文件或其任何補充、修訂或更換附頁，並不會引 ...

The Stock Exchange of Hong Kong Limited and the Securities and Futures Commission take no responsibility for the contents of this Application Proof, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this Application Proof. Application Proof of BenQ BM Holding Cayman Corp. 明基醫院集團股份有限公司 (the "Company") (A company incorporated in the Cayman Islands with limite ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並表明概不就因本公告全部或任何部分內容而產生或依賴該等內 容而引致的任何損失承擔任何責任。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 1 (a) 在聯交所網站登載本公告，並不會引致本公司、其聯席保薦人、整體協調 人、顧問或包銷團成員須於香港或任何其他司法管轄區進行發售或配售活動 的任何責任。本公司最終會否進行發售或配售仍屬未知之數； (b) 本公告所涉及的上市申請並未獲批准，聯交所及證監會或會接納、發回或拒 絕有關的公開發售及╱或上市申請； (c) 本公告不應被視為勸誘認購或購買任何證券，亦不擬構成該等勸誘； (d) 本公司或其任何聯屬人士、其顧問或包銷團成員概無通過刊發本公告而於任 何司法管轄區發售任何證券或招攬要約認購或購買任何證券； (e) 本公告（及其所載資料）僅供參考，並不構成或組成在美國（包括其領土及屬 地、美國任何州及哥倫比 ...

香港聯合交易所有限公司及證券及期貨事務監察委員會對本申請版本的內容概不負責，對其準確性或完整 性亦不發表任何聲明，並表明概不就因本申請版本全部或任何部分內容而產生或依賴該等內容而引致的任 何損失承擔任何責任。 BenQ BM Holding Cayman Corp. 明基醫院集團股份有限公司 （「本公司」） （於開曼群島註冊成立的有限公司） 申請版本 警告 本申請版本乃根據香港聯合交易所有限公司（「聯交所」）及證券及期貨事務監察委員會的要求而刊發，僅 用作向香港公眾人士提供資料。 本申請版本為草擬本，其所載資料並不完整，亦可能會作出重大變動。閣下閱覽本文件，即表示閣下知 悉、接納並向本公司、其各自的聯席保薦人、整體協調人、顧問及包銷團成員表示同意： | [編纂]項下的[編纂]數目 | ： | [編纂] | | --- | --- | --- | | | | （視乎[編纂]行使情況而定） | | [編纂]數目 | ： | [編纂（可予重新分配） ] | | [編纂]數目 | ： | [編纂] | | | | （可予重新分配及視乎 | | | | [編纂]行使情況而定） | | 最高[編纂] | ： | 每股[編 ...